PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29040023-2 2017 We report a patient with disseminated LGG with the BRAFV600E mutation, which was refractory to selumetinib, a MEK inhibitor, but subsequently showed immediate clinical and radiographic response to dabrafenib, a BRAF inhibitor, with sustained effect for 9 months prior to clinical progression. AZD 6244 95-106 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 51-55